Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Recruiting Observational Study
Epidermolysis Bullosa Dystrophica
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
70 (estimated)
Sponsor
Stanford University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether s…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of RDEB by local dermatologist * 7 years of age or older Exclusion Criteria: -Medical instability limiting ability to travel to Stanford University Medical Center
Contacts

Irene Bailey-Healy

(650) 721-7149

baileyhi@stanford.edu

CONTACT